See more : Greggs plc (GGGSF) Income Statement Analysis – Financial Results
Complete financial analysis of Seer, Inc. (SEER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seer, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jahez International Company for Information Systems Technology (9526.SR) Income Statement Analysis – Financial Results
- Nektar Therapeutics (NKTR) Income Statement Analysis – Financial Results
- Groupe Gorgé SA (GOE.PA) Income Statement Analysis – Financial Results
- Projektengagemang Sweden AB (publ) (PENG-B.ST) Income Statement Analysis – Financial Results
- Frontier Energy Corporation (FRGY) Income Statement Analysis – Financial Results
Seer, Inc. (SEER)
About Seer, Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 15.18M | 14.69M | 6.39M | 656.00K | 58.00K | 0.00 |
| Cost of Revenue | 8.16M | 7.94M | 3.21M | 0.00 | 701.00K | 100.00K |
| Gross Profit | 7.03M | 6.74M | 3.19M | 656.00K | -643.00K | -100.00K |
| Gross Profit Ratio | 46.29% | 45.91% | 49.87% | 100.00% | -1,108.62% | 0.00% |
| Research & Development | 53.02M | 45.80M | 29.12M | 18.94M | 12.39M | 3.78M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 15.36M | 4.61M | 2.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 58.95M | 58.53M | 45.76M | 15.36M | 4.61M | 2.98M |
| Other Expenses | 0.00 | -351.00K | -223.00K | -9.00K | -58.00K | 0.00 |
| Operating Expenses | 111.97M | 103.98M | 74.66M | 34.31M | 16.94M | 6.76M |
| Cost & Expenses | 120.12M | 111.92M | 77.87M | 34.31M | 16.94M | 6.76M |
| Interest Income | 17.76M | 4.60M | 326.00K | 883.00K | 850.00K | 451.00K |
| Interest Expense | 0.00 | 327.00K | 22.00K | 9.00K | 5.00K | 0.00 |
| Depreciation & Amortization | 5.58M | 5.90M | 3.56M | 1.61M | 701.00K | 100.00K |
| EBITDA | -97.89M | -93.29M | -68.59M | -31.17M | -15.33M | -6.21M |
| EBITDA Ratio | -644.74% | -633.07% | -1,112.72% | -4,994.82% | -26,434.48% | 0.00% |
| Operating Income | -103.46M | -97.24M | -71.47M | -33.65M | -16.88M | -6.76M |
| Operating Income Ratio | -681.48% | -662.14% | -1,117.81% | -5,129.42% | -29,108.62% | 0.00% |
| Total Other Income/Expenses | 17.19M | 4.27M | 304.00K | 874.00K | 845.00K | 451.00K |
| Income Before Tax | -86.28M | -92.97M | -71.17M | -32.78M | -16.04M | -6.31M |
| Income Before Tax Ratio | -568.28% | -633.07% | -1,113.06% | -4,996.19% | -27,651.72% | 0.00% |
| Income Tax Expense | 0.00 | -4.27M | -2.54M | -1.61M | 5.00K | 451.00K |
| Net Income | -86.28M | -88.70M | -68.63M | -31.17M | -16.04M | -6.31M |
| Net Income Ratio | -568.28% | -604.00% | -1,073.40% | -4,751.37% | -27,660.34% | 0.00% |
| EPS | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| EPS Diluted | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| Weighted Avg Shares Out | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
| Weighted Avg Shares Out (Dil) | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
Seer to Present at the J.P. Morgan 41st Annual Health Care Conference
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) CEO Omid Farokhzad on Q3 2022 Results - Earnings Call Transcript
Seer to Report Third Quarter 2022 Financial Results on November 8, 2022
Seer to Participate in the Morgan Stanley Global Healthcare Conference
Seer, Inc. (SEER) CEO Omid Farokhzad on Q2 2022 Results - Earnings Call Transcript
Seer, Inc. (SEER) Reports Q2 Loss, Tops Revenue Estimates
Seer to Report Second Quarter 2022 Financial Results on August 9, 2022
Seer, Inc. (SEER) CEO Omid Farokhzad on Q1 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports